Covered Companies: enVVeno Medical

Most Recent Event

Closing Bell

June 9, 2026  4:00 PM ET

Rob Berman, CEO discussed the Company’s recently reported IDE approval of its enVVe® System, marking a first-ever FDA
IDE approval for a U.S. pivotal study of a
non-surgical replacement venous valve.

enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease.

NASDAQ: NVNO

About

enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company is currently developing the enVVe system, which includes a first-in-class non-surgical replacement venous valve being developed for the treatment of severe Deep Venous Insufficiency (DVI). The enVVe valve is designed to act as one-way valve, to help assist in propelling blood up the leg, and back to the heart and lungs. As a transcatheter delivered device, the enVVe procedure will be performed under light sedation and should not require an over-night hospital stay.

Past Events

“What This Means”

May 12, 2026

Rob Berman, CEO discusses the Company’s recent news announcing the U.S. Food and Drug Administration’s (FDA) first-ever IDE approval awarded to enVVeno to proceed with a U.S. pivotal study of a non-surgical replacement venous valve.

“CEO Connect”

Wednesday, December 3, 2025

 

Join Us

Sign up for email alerts to stay up-to-date on the latest Virtual Investor events

If you are interested in joining our roster of covered companies and participating in our events, sign up here: